Abstract
Mammalian cells depend on extracellular input for the regulation of growth, proliferation and survival. Cancer cells evade these requirements, and are able to take up nutrients in a cell-autonomous fashion, which allows continuous growth and proliferation. To fulfill the high bioenergetic demands imposed by transformation, tumors must develop alternative mechanisms of energy production. Accordingly, the biochemical signature of cancer cells involves a shift to aerobic glycolysis, also known as the «Warburg effect». This property of cancer cells has resulted of great utility in modern medicine for detection of early tumors by positron-emission scanning. Nonetheless, the underlying mechanisms and contribution of the Warburg effect to the malignant phenotype have remained obscure. Thanks to recent advances in cancer research, we are beginning to understand the link between cancer genetics and the abnormal use of glucose by tumors. A new scenario is thus emerging, in which bioenergetics would contribute to and sustain malignant transformation. These findings are not only important for a better understanding of tumorigenesis; tumor reliance on glycolysis can be exploited in the search for novel, more potent therapeutic approaches to cancer treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hanahan D, Weinberg R. The hallmarks of cancer. Cell, 2000;100:57–70.
Hammerman P, Fox C, Thompson C. Beginnings of a signal-transduction pathway for bioenergetic control of cell survival. Trends Biochem Sci. 2004;15:259–66.
Warburg O. On the origin of cancer cells. Science, 1956;123:309–14.
Gambhir S. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer, 2002;2:683–93.
Baysal B, Ferrell R, Willett-Brozick J, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 2000;287:848–51.
Tomlinson I. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Gen. 2002;30: 406–10.
Selak M, Armour S, MacKenzie E, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005;7:77–85.
Semenza G. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med. 2001;7:345–50.
Semenza G. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 2003;3:721–32.
Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer. 2003;107:873–7.
Fresno Vara J, Casado E, de Castro, J, et al. P13K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30:193–204.
Engelman J, Luo J, Cantley L. The evaolution of P13 kinases as regulators of growth and metabolism. Nat Review Genet. 2006;441:606–19.
Majewski N. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell. 2004;16:819–30.
Kahn B, Alquier T, Carling D, et al. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005; 1:15–25.
Jones R, Plas D, Kubek S, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005;18:283–93.
Corradetti M, Inoki K, Bardeesy N, et al. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev. 2004;18:1533–8.
Wullschlege R, Loewith R, Hall M. TOR signaling in growth and metabolism. Cell. 2006;124:471–84.
Li Y CM, Inoki K, Guan KL. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem Sci. 2004;29:32–8.
Manning B, Cantley L. Rheb fills a GAP between TSC and TOR. Trends Biochem Sci. 2003;28:573–6.
Inoki K, Zhu T, Guan K. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115:577–90.
Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004;18:2893–904.
Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov, 2006;2:132–4.
Kondoh H, Lleonart M, Gil J, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005;65:177–85.
Kim JW, Dang CV: Multifaceted roles of glycolytic enzymes. Trends Biochem Sci. 2005;30:142–50.
Gottlob K, Majewski N, Kennedy S, et al. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 2001;15:1406–18.
Sun Y, Chou C, Chen W, et al. The crystal structure of a multifunctional protein: phosphoglucose isomerase/autocrine motility factor/neuroleukin. Proc Natl Acad Sci USA. 1999;96:5412–7.
Zheng L, Roeder R, Luo Y. S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell Metab. 2003; 114:255–66.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by an unrestricted educational grant from Pfizer.
Rights and permissions
About this article
Cite this article
Mérida, I., Ávila-Flores, A. Tumor metabolism: new opportunities for cancer therapy. Clin Transl Oncol 8, 711–716 (2006). https://doi.org/10.1007/s12094-006-0117-6
Issue Date:
DOI: https://doi.org/10.1007/s12094-006-0117-6